BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strosberg JR, Fisher GA, Benson AB, Malin JL, Cherepanov D, Broder MS, Anthony LB, Arslan B, Fisher GA, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples W, Philip PA, Strosberg J, Wolin EM; GEPNET Treatment Consensus Panel. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas 2013;42:397-404. [PMID: 23211372 DOI: 10.1097/MPA.0b013e31826d3a17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Broder MS, Gibbs SN, Yermilov I. An Adaptation of the RAND/UCLA Modified Delphi Panel Method in the Time of COVID-19. JHL 2022;Volume 14:63-70. [DOI: 10.2147/jhl.s352500] [Reference Citation Analysis]
2 Wu J, Xue C, Du X, Tong M, Miao X. Study on Ergonomic Digital Evaluation System for the Naval Shipborne Command Cabin Based on Extended JACK. J Phys : Conf Ser 2021;1748:062010. [DOI: 10.1088/1742-6596/1748/6/062010] [Reference Citation Analysis]
3 Døssing KBV, Kjær C, Vikeså J, Binderup T, Knigge U, Culler MD, Kjær A, Federspiel B, Friis-Hansen L. Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells. Genes (Basel) 2018;9:E337. [PMID: 29973528 DOI: 10.3390/genes9070337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Geer EB, Ayala A, Bonert V, Carmichael JD, Gordon MB, Katznelson L, Manuylova E, Shafiq I, Surampudi V, Swerdloff RS, Broder MS, Cherepanov D, Eagan M, Lee J, Said Q, Neary MP, Biller BMK. Follow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians. Pituitary 2017;20:422-9. [PMID: 28275992 DOI: 10.1007/s11102-017-0801-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
5 Cuyle PJ, Prenen H. Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors. Ann Gastroenterol. 2018;31:140-150. [PMID: 29507461 DOI: 10.20524/aog.2018.0224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Aerts M, Reynaert H. Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report. Case Rep Gastroenterol 2017;11:616-23. [PMID: 29430219 DOI: 10.1159/000485025] [Reference Citation Analysis]
7 Pokuri VK, Fong MK, Iyer R. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep 2016;18:7. [PMID: 26743514 DOI: 10.1007/s11912-015-0492-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
8 Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, Cwikla J, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, Virgolini I, Kjaer A, Modlin IM. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 2016;5:174-87. [PMID: 27582247 DOI: 10.1530/EC-16-0043] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
9 Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16:e435-e446. [PMID: 26370353 DOI: 10.1016/s1470-2045(15)00186-2] [Cited by in Crossref: 161] [Cited by in F6Publishing: 142] [Article Influence: 20.1] [Reference Citation Analysis]
10 Strosberg JR, Fisher GA, Benson AB, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples WJ, Philip PA, Wolin EM, Cherepanov D, Broder MS. Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World J Gastroenterol 2015; 21(8): 2450-2459 [PMID: 25741154 DOI: 10.3748/wjg.v21.i8.2450] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
11 Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J Gastroenterol 2015; 21(6): 1945-1955 [PMID: 25684964 DOI: 10.3748/wjg.v21.i6.1945] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
12 Kilickap S, Yalcin S. Carcinoid Syndrome. Neuroendocrine Tumours 2015. [DOI: 10.1007/978-3-662-45215-8_29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19:930-936. [PMID: 25096997 DOI: 10.1634/theoncologist.2014-0120] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 7.9] [Reference Citation Analysis]